Glycyx

Glycyx Therapeutics, headquartered in San Francisco, California, is a small biotech firm with three employees. The company focuses on developing innovative cancer treatments. Glycyx specializes in addressing the challenge of opioids hindering immunotherapy effectiveness. Their research centers around Opioid-Induced Immunotherapy Failure (OIIF), a condition where opioids diminish the body's immune response to cancer cells, compromising the efficacy of immune checkpoint inhibitors (ICIs). To combat this issue, Glycyx is developing axelopran, a small molecule peripherally restricted opioid antagonist. Axelopran is designed to counteract the negative effects of opioids on ICIs without compromising pain relief. The drug aims to reverse opioid-induced immunosuppression, enable re-challenge in treatment-resistant cancers, and offer robust safety credentials established through earlier studies and demonstrated efficacy in preclinical settings. Glycyx Therapeutics can be contacted via their website, glycyxtherapeutics.com.